News and Announcements
PromarkerD Shows Improved Predictive Ability & Robustness
- Published December 15, 2016 3:19PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International Laboratories Ltd (ASX: PIQ) is pleased to provide an update on its clinical studies for PromarkerD, the company’s breakthrough test for the prediction of diabetic kidney disease.
Highlights:
- PromarkerD predicts diabetic kidney disease across all major clinical definitions of rapid decline in kidney function
- Predictive ability improved – PromarkerD correctly predicted 61-97% of individuals who went on to have a clinically significant decline in kidney function within four years
- Inter-laboratory study shows robustness of PromarkerD as a future Laboratory Developed Test
There are currently 415 million adults worldwide with diabetes, and approximately one third of these people have chronic kidney disease which can lead to dialysis or kidney transplant.
To read the full announcements please click on the button below.